The Cooper Companies, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

CooperCompanies (COO) Keeps CooperSurgical and Expands Buybacks. What Did the Strategic Review Reveal?

Business restructuring Share buyback AI-generated analysis

πŸ›οΈ The Board unanimously decided to retain the CooperSurgical unit after rejecting sale offers deemed not in shareholders' best interest.

πŸ’° The company expanded its share repurchase program from $2 billion to $3 billion following $445 million in buybacks executed this fiscal year.

πŸ“ˆ Adjusted diluted EPS increased 4% year-over-year to $1.15, reflecting a 4% jump from Q3 FY25 despite marginal top-line growth.

πŸ“‰ Adjusted gross margins declined by 60 basis points compared to the prior year due to higher manufacturing costs and currency fluctuations.

πŸ‘οΈ CooperVision segment delivered flat organic growth hindered by challenges in the Asia Pacific and Americas regions.

πŸ” The sphere and other lens category within CooperVision declined 1% organically year-over-year during the third quarter.

πŸš€ Management plans to grow the global sales and marketing organization for CooperVision to drive future revenue expansion.

βœ‚οΈ The company is prioritizing cost-cutting measures, efficiency initiatives, and revised inventory and logistics programs.

πŸ“Š Institutional interest remains steady with 52 hedge funds holding positions as of Q2 2026, up from 49 in the previous quarter.

🏦 BlackRock remains the largest institutional investor, owning 7.71% of outstanding shares.

Bullish Signals
  • The Board unanimously decided to retain the CooperSurgical unit after concluding that sale offers were not in shareholders' best interest.
  • The company expanded its share repurchase program from $2 billion to $3 billion, signaling management confidence in business fundamentals.
  • Adjusted diluted EPS increased 4% year-over-year to $1.15, demonstrating improved profitability despite marginal revenue growth.
Risk Factors
  • Adjusted gross margins contracted by 60 basis points compared to the prior year due to higher manufacturing costs and currency fluctuations.
  • CooperVision segment delivered flat organic growth hindered by specific challenges across the Asia Pacific and Americas regions.
  • The sphere and other lens category within CooperVision declined 1% organically year-over-year during the third quarter.
Full Analysis
The Cooper Companies (COO) has concluded its strategic review process, deciding to retain its CooperSurgical unit rather than sell it. The Board determined that the valuation offers received were not in shareholders' best interest and acknowledged temporary drivers affecting the unit's valuation gap. Despite retaining CooperSurgical, the company faces near-term headwinds with marginal top-line growth of 1% year-over-year in the third quarter. Adjusted diluted EPS rose 4% to $1.15, but adjusted gross margins contracted by 60 basis points due to higher manufacturing costs and currency fluctuations. To support shareholder value amidst these challenges, Cooper Companies expanded its share repurchase program from $2 billion to $3 billion after executing $445 million in buybacks during the fiscal year. Management also plans operational improvements, including growing the global sales organization for CooperVision and implementing cost-cutting measures.